These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 9321739

  • 21. Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies.
    Chapman AB.
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1197-204. PubMed ID: 18579674
    [Abstract] [Full Text] [Related]

  • 22. Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease.
    Ecder T, Schrier RW.
    Nat Rev Nephrol; 2009 Apr; 5(4):221-8. PubMed ID: 19322187
    [Abstract] [Full Text] [Related]

  • 23. Cardiovascular complications in autosomal dominant polycystic kidney disease.
    Ecder T.
    Curr Hypertens Rev; 2013 Feb; 9(1):2-11. PubMed ID: 23971638
    [Abstract] [Full Text] [Related]

  • 24. Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease.
    Ecder T, Edelstein CL, Chapman AB, Johnson AM, Tison L, Gill EA, Brosnahan GM, Schrier RW.
    Nephrol Dial Transplant; 1999 May; 14(5):1113-6. PubMed ID: 10344347
    [Abstract] [Full Text] [Related]

  • 25. Optimal care of autosomal dominant polycystic kidney disease patients.
    Schrier RW.
    Nephrology (Carlton); 2006 Apr; 11(2):124-30. PubMed ID: 16669974
    [Abstract] [Full Text] [Related]

  • 26. Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade?
    Brosnahan GM, Abebe KZ, Moore CG, Bae KT, Braun WE, Chapman AB, Flessner MF, Harris PC, Hogan MC, Perrone RD, Rahbari-Oskoui FF, Steinman TI, Torres VE, The Halt Pkd Investigators.
    Curr Hypertens Rev; 2018 Apr; 14(1):39-47. PubMed ID: 29564978
    [Abstract] [Full Text] [Related]

  • 27. Interpretation of renal volume in autosomal dominant polycystic kidney disease and relevant clinical implications.
    Masoumi A, Elhassan E, Schrier RW.
    Iran J Kidney Dis; 2011 Jan; 5(1):1-8. PubMed ID: 21189426
    [Abstract] [Full Text] [Related]

  • 28. Urinary renin-angiotensin markers in polycystic kidney disease.
    Salih M, Bovée DM, Roksnoer LCW, Casteleijn NF, Bakker SJL, Gansevoort RT, Zietse R, Danser AHJ, Hoorn EJ.
    Am J Physiol Renal Physiol; 2017 Oct 01; 313(4):F874-F881. PubMed ID: 28747358
    [Abstract] [Full Text] [Related]

  • 29. [Hypertension in patients with polycystic kidney disease -  incidence, pathogenesis, prognosis, therapy].
    Tesař V, Reiterová J.
    Vnitr Lek; 2013 Jun 01; 59(6):496-500. PubMed ID: 23808746
    [Abstract] [Full Text] [Related]

  • 30. Renal vascular resistance and renin-angiotensin system in the pathogenesis of early hypertension in autosomal dominant polycystic kidney disease.
    Ramunni A, Saracino A, Esposito T, Saliani MT, Coratelli P.
    Hypertens Res; 2004 Apr 01; 27(4):221-5. PubMed ID: 15127878
    [Abstract] [Full Text] [Related]

  • 31. Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease.
    Clark LA, Whitmire S, Patton S, Clark C, Blanchette CM, Howden R.
    J Med Econ; 2017 Jul 01; 20(7):715-722. PubMed ID: 28332417
    [Abstract] [Full Text] [Related]

  • 32. Increased urinary Angiotensinogen/Creatinine (AGT/Cr) ratio may be associated with reduced renal function in autosomal dominant polycystic kidney disease patients.
    Park HC, Kang AY, Jang JY, Kim H, Han M, Oh KH, Kim SH, Noh JW, Cheong HI, Hwang YH, Ahn C.
    BMC Nephrol; 2015 Jun 20; 16():86. PubMed ID: 26092580
    [Abstract] [Full Text] [Related]

  • 33. Role of renin-angiotensin-aldosterone system and of sympathetic activity in arterial hypertension associated with autosomal dominant polycystic kidney disease.
    Cerasola G, Li Vecchi M, Mulé G, Cottone S, Mangano MT, Andronico G, Contomo A, Parrino IA, Renda F, Pavone G, Scialabba A.
    Contrib Nephrol; 1997 Jun 20; 122():22-7. PubMed ID: 9399032
    [No Abstract] [Full Text] [Related]

  • 34. The effects of the renin-angiotensin-aldosterone system blockers on serum ischemia-modified albumin levels in autosomal dominant polycystic kidney disease.
    Ermurat S, Güllülü M, Sarandöl E.
    Ir J Med Sci; 2022 Dec 20; 191(6):2777-2783. PubMed ID: 35067861
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Angiotensinogen and angiotensin II type 1 receptor gene polymorphism in patients with autosomal dominant polycystic kidney disease: effect on hypertension and ESRD.
    Lee KB, Kim UK.
    Yonsei Med J; 2003 Aug 30; 44(4):641-7. PubMed ID: 12950120
    [Abstract] [Full Text] [Related]

  • 39. Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease.
    Schrier RW, McFann KK, Johnson AM.
    Kidney Int; 2003 Feb 30; 63(2):678-85. PubMed ID: 12631134
    [Abstract] [Full Text] [Related]

  • 40. Left ventricular hypertrophy in hypertensive patients with autosomal dominant polycystic kidney disease: influence of blood pressure and humoral and neurohormonal factors.
    Martinez-Vea A, Valero FA, Bardaji A, Gutierrez C, Broch M, Garcia C, Richart C, Oliver JA.
    Am J Nephrol; 2000 Feb 30; 20(3):193-200. PubMed ID: 10878400
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.